Business Wire

DEEPTECH-LABS

14.6.2022 09:02:09 CEST | Business Wire | Press release

Share
Europe’s Only Deeptech Demo Day: Deeptech Labs’ Unveil 6 New Accelerator Start-ups

Deeptech Labs , the accelerator and VC fund for post-Seed, pre-Series A deeptech companies will unveil its Spring cohort of 6 deeptech start-ups to an online audience of investors on 21st June. More than 120 VCs and Corporate Entities have previously attended its virtual demo days, demonstrating the significant and growing interest in the European deeptech sector.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220614005112/en/

Deeptech Labs is a Cambridge-based accelerator programme and VC fund, founded in 2020 by ARM, Cambridge Innovation Capital, Martlet Capital, Ewan Kirk and the University of Cambridge. The accelerator supports deeptech entrepreneurs as they move from prototype and proof of concept to scalable products and services, and connects them to Deeptech Labs’ extensive network of deeptech investors.

The Deeptech Labs accelerator programme and investment fund was founded to fill a significant gap in the European venture market and accelerate the growth of promising early-stage deeptech companies. Deeptech Labs supports its cohort companies through a specially-designed thirteen week accelerator programme, connecting founders with a global network of more than 50 world-leading deeptech entrepreneurs, technology experts and investors.

Watch Demo Day elevator pitches from the Spring ’22 cohort:

Anaphite (Bristol, UK) incorporates graphene into battery materials, to enable the creation of super-fast charge, long-range batteries - something that will have significant impact on the EV market.

  • Watch Anaphite’s 3-minute elevator pitch here

Toposens (Munich, Germany) is the world’s only 3D ultrasonic sensing technology for advanced collision avoidance. It uses echolocation and signal processing algorithms to make autonomous vehicles in the robotics and automotive industry smarter and safer.

  • Watch Toposens’ 3-minute elevator pitch here

SonicEdge (Shoham, Israel) has developed the world’s smallest speaker-in-chip that uses breakthrough ultrasound technology to completely transform the audio experience.

  • Watch SonicEdge’s 3-minute elevator pitch here

iKVA (Cambridge, UK) is an early-stage AI Knowledge Management company creating solutions for organisations to discover data and intelligently and proactively provide it to users when they need it, enabling better business insights.

  • Watch iKVA’s 3-minute elevator pitch here

Inovo Robotics (Guildford, UK) are democratising robotics with modular, no-code, low cost “cobots” that open up completely new opportunities for safe, flexible automation.

  • Watch Inovo Robotics’ 3-minute elevator pitch here

Nestwave (Paris, France) Nestwave provides advanced, IoT geolocation solutions to IoT modem and DSP vendors to significantly improve localization accuracy in critical indoor and dense urban environments while greatly reducing power consumption and solution footprint.

  • Watch Nestwave’s 3-minute elevator pitch here

Miles Kirby, CEO Deeptech Labs said, “Europe has a number of global advantages in deeptech – we have 50% of the world’s best universities and the highest number of highly cited research papers - but there’s a disparity when it comes to European investment in deeptech companies. European deeptech companies attract $33 billion compared to $144 billion in the US .

Thanks to our deeptech-specific accelerator programme, our cohort companies are stronger, more resilient and have highly focused go-to-market strategies and that’s why so many investors attend our Demo Days – and how we are helping to fix the European deeptech investment gap.”

  • Watch Miles’ 5 minute introduction to Deeptech Labs here .

Editors Notes

Deeptech Labs is an accelerator, VC fund, and the catalyst for deeptech success. Twice a year, its cohort of start-ups are embedded in a powerful network of successful entrepreneurs, expert practitioners, leading researchers, and deeptech organisations worldwide. Deeptech Labs is founded by ARM, Cambridge Innovation Capital, Martlet Capital, Ewan Kirk and the University of Cambridge - forefront institutions and individuals at the heart of the Cambridge and global technology ecosystems.

The company is headquartered in Cambridge, UK.

For more information, please visit dtl.vc

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States1.7.2026 07:00:00 CEST | Press release

Galderma received a Complete Response Letter from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization Relfydess is approved in 33 markets and already launched in more than 20, including across Europe, the Middle East and Australia, with an encouraging early launch trajectory supported by positive healthcare professional feedback Regulatory filings in other territories are ongoing and remain on track Ad hoc announcement pursuant to Art. 53 LR Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. Food and Drug Administration (“FDA”). The Company has received a Complete Response Letter (CRL) from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization. As part of its review, the FDA conducted a Pre-License Inspection (PLI) of Galderma’s manufa

EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 03:45:00 CEST | Press release

EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia

Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release

Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting

FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release

FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease

Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release

Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye